Detailed Analysis of Melanin-Concentrating Hormone Receptor 1 Market| Business Growth, Development Factors, Current and Future Trends till 2030 | Oracle, Kenexa, Halogen Software, SAP, Ceridian

Melanin-concentrating hormone receptor 1 market is anticipated to grow at a significant CAGR during the forecast period. Melanin-concentrating hormone (MCH) is a neuropeptide in the central and peripheral nervous systems that control feeding behaviours and energy metabolism. The major factor contributing to the growth of the market is the increasing prevalence of obesity across the globe. According to the World Health Organization (WHO), an estimated 38.2 million children under the age of 5 years were overweight or obese in 2019. Additionally, the number of overweight children under 5 has increased by nearly 24% since 2000 in Africa. Furthermore, almost half of the children under 5 who were overweight or obese lived in Asia in 2019. Apart from this, in 2020, an estimated 39 million children under the age of 5 were overweight or obese. Moreover, as per the same source, more than 1.9 billion adults, 18 years and older, were overweight out of which over 650 million were obese in 2016.

Some major players in the market include AstraZeneca Plc, Takeda Pharmaceutical Co., Ltd., and Boehringer Ingelheim GmbH, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Harmony Biosciences Holdings, Inc. announced the acquisition of HBS-102 from ConSynance Therapeutics Inc. HBS-102 is a Melanin Concentrating Hormone Receptor 1 antagonist to offer a novel approach to the treatment of narcolepsy that includes the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations and sleeps paralysis.

To Request a Sample of our Report on Melanin-Concentrating Hormone Receptor 1 Market: https://www.omrglobal.com/request-sample/melanin-concentrating-hormone-receptor-1-market

Market Coverage

• Market number available for - 2023-2030

• Base year- 2022

• Forecast period- 2024-2030

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- AstraZeneca Plc, Takeda Pharmaceutical Co., Ltd., and Boehringer Ingelheim GmbH, among others.

Melanin-Concentrating Hormone Receptor 1 Market Report by Segment

By Type

• ALB-127158(a)

• AZ-13483342

• AZD-3857

• BI-186908

• Others

By Application

• Obesity

• Inflammatory Bowel Disease

• Non-Alcoholic Steatohepatitis

• Others

A full Report of Melanin-Concentrating Hormone Receptor 1 Market is Available @ https://www.omrglobal.com/industry-reports/melanin-concentrating-hormone-receptor-1-market

Melanin-Concentrating Hormone Receptor 1 Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.